Amide Active Ingredients TRIZ Cases

Small molecules selectively increase RAD51 activity in normal cells to repair DNA while sensitizing cancer cells to therapies.

Carbonic anhydrase inhibitors target enzyme activity to suppress type 2 inflammation while minimizing side effects from conventional helminth treatments.

Administers combined agents targeting Gs, Gq, and Gi pathways to reduce toxic all-trans-retinal accumulation and reactive oxygen species in the retina.

A tamsulosin solid composition uses a low-water-solubility disintegrant dispersed in a matrix former to achieve stable drug release.

Pairing selective HDAC6 inhibitors with immunomodulatory drugs overcomes dose-limiting toxicities while enhancing antitumor efficacy in lymphoma treatment.

Combining palmitoylethanolamide with silymarin delivers synergistic therapeutic effects for renal diseases.

Cabozantinib (S)-malate tablets achieve a 19% higher Cmax than capsules, improving progression-free survival in advanced renal cell carcinoma.

Echinacea alkamides activate CB1 receptors to stimulate appetite and slow metabolism, overcoming the inefficacy of conventional weight gain shakes.

Iron chelators deplete intracellular iron to overcome hypoxia-induced resistance, inducing irreversible proliferation arrest in resistant tumor sections.

Ivaltinostat maintains disease stability after fluoropyrimidine induction, reducing cumulative toxicity while preserving therapeutic efficacy.

Lipid nanoparticles encapsulate long-chain ceramides to resolve solubility contradictions and induce targeted cancer cell apoptosis.

HIF-1 inhibitors destroy keloid tissue by blocking glycolytic metabolism to prevent surgical recurrence.

Carboxyl-containing acrylic adhesive copolymer sustains silodosin dissolution, preventing crystallization and boosting skin permeability.

A film coating layer uses a mixed solvent of water and organic solvent to dissolve polyvinyl alcohol polymers.

A liquid-filled hard gel capsule formulation uses a non-emulsified triglyceride mixture to solubilize dutasteride.

Glyceryl behenate in a sustained release phase stabilizes thiocolchicoside plasma levels, reducing dosing frequency while maintaining tablet physical integrity.

Replacing maltose and PVP with non-reactive excipients prevents Maillard reactions and peroxide impurities in the pharmaceutical formulation.

Histone deacetylase inhibitors modulate Program Death Receptor Ligand 1 expression in melanoma cells.

HMBA analogs induce HEXIM1 expression without causing thrombocytopenia or dose-dependent toxicity.

M2-selective muscarinic receptor blockers modulate autonomic pathways to reduce atrial fibrillation incidence while minimizing treatment complications.

Selective diethyl-naphthalene HDAC inhibitor reduces spleen volume and toxicity in myeloproliferative syndromes.

Direct application of thioglycolate breaks disulfide bonds in cancer cells, killing tumors and microorganisms without systemic side effects.

HDAC and DNMT inhibitors prevent histone deacetylation and DNA methylation, reducing myocardial infarct volume and morbidity during ischemic injury.

Sulcardine achieves therapeutic efficacy through atrial selectivity.

4-PBA binds COPII proteins to release GRP94 from endoplasmic reticulum retention for enhanced immunotherapy.

MEK, ERK, and Raf inhibitors block the adhesion of sickle red blood cells to endothelial surfaces.

Post-transcriptional utrophin upregulator compounds increase protein expression to reduce muscle wasting without corticosteroid side effects.

A solid crystalline co-crystal unites DFMO and AMXT 1501 into a single dosage form.

Sustained-release pellets combine hydroxypropyl methylcellulose and acid-resistant acrylic polymer to control drug dissolution.

Nanoparticle carriers mitigate renal and cardiac toxicity from high-dose suramin while inhibiting tumor migration.

A 20-HETE synthesizing enzyme inhibitor reduces cystic epithelial cell proliferation in mammalian kidneys.

Acid gelatin soft capsules prevent cross-linking during storage, maintaining dutasteride bioavailability and stability.

Modular small molecules inhibit STAT3 phosphorylation to treat refractory cancer, inflammation, and fibrosis conditions.

Steroid sulfatase inhibitors resolve inadequate preterm labor treatments by modulating hormonal balance.

A powder pharmaceutical composition combines calcium acetate, aluminum sulfate, and an oxidizing agent to form aqueous dispersions for topical skin treatment.

Phase inversion temperature forms stable ceramide nano-emulsions, reducing energy consumption and production costs compared to high-pressure homogenization.

Amide-modified N-acetylcysteine derivatives cross the blood-brain barrier to mitigate cognitive decline and neurodegeneration associated with ferroptosis.

Metronomic benzenesulfonamide therapy manages canine malignant peripheral nerve sheath tumors while minimizing adverse effects from conventional chemotherapy.

Formula I compounds inhibit secretory leukocyte protease inhibitor secretion, blocking the Rb and FoxM1 pathway to reduce cancer metastasis.